Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Jan 22;21(3):725.
doi: 10.3390/ijms21030725.

The Influence of Inflammation on Anemia in CKD Patients

Anna Gluba-Brzózka  1 , Beata Franczyk  1 , Robert Olszewski  2 , Jacek Rysz  1
Affiliations
Review

The Influence of Inflammation on Anemia in CKD Patients

Anna Gluba-Brzózka et al. Int J Mol Sci. .

Abstract

Anemia is frequently observed in the course of chronic kidney disease (CKD) and it is associated with diminishing the quality of a patient's life. It also enhances morbidity and mortality and hastens the CKD progression rate. Patients with CKD frequently suffer from a chronic inflammatory state which is related to a vast range of underlying factors. The results of studies have demonstrated that persistent inflammation may contribute to the variability in Hb levels and hyporesponsiveness to erythropoietin stimulating agents (ESA), which are frequently observed in CKD patients. The understanding of the impact of inflammatory cytokines on erythropoietin production and hepcidin synthesis will enable one to unravel the net of interactions of multiple factors involved in the pathogenesis of the anemia of chronic disease. It seems that anti-cytokine and anti-oxidative treatment strategies may be the future of pharmacological interventions aiming at the treatment of inflammation-associated hyporesponsiveness to ESA. The discovery of new therapeutic approaches towards the treatment of anemia in CKD patients has become highly awaited. The treatment of anemia with erythropoietin (EPO) was associated with great benefits for some patients but not all.

Keywords: ESA hyporesponsiveness; anemia; anemia of inflammation; chronic kidney disease; inflammation.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

References

    1. Cases A., Egocheaga M.I., Tranche S., Pallarés V., Ojeda R., Górriz J.L., Portolés J.M. Anemia of chronic kidney disease: Protocol of study, management and referral to Nephrology. Nefrologia. 2018;38:8–12. doi: 10.1016/j.nefro.2017.09.004. - DOI - PubMed
    1. Malyszko J., Mysliwiec M. Hepcidin in anemia and inflammation in chronic kidney disease. Kidney Blood Press Res. 2007;30:15–30. doi: 10.1159/000098522. - DOI - PubMed
    1. Poole S., Bird T.A., Selkirk S., Gaines-Das R.E., Choudry Y., Stephenson S.L., Kenny A.J., Saklatvaa J. Fate of injected interleukin-1 in rats: Sequestration and degradation in the kidney. Cytokine. 1990;2:416–422. doi: 10.1016/1043-4666(90)90050-4. - DOI - PubMed
    1. Panichi V., Migliori M., De Pietro S., Taccola D., Bianchi A.M., Norpoth M., Metelli M.R., Giovannini L., Tetta C., Palla R. C-reactive protein in patients with chronic renal diseases. Ren. Fail. 2001;23:551–562. - PubMed
    1. Stenvinkel P., Heimburger O., Wang T., Lindholm B., Bergstrom J., Elinder C.G. High serum hyaluronan indicates poor survival in renal replacement therapy. Am. J. Kidney Dis. 1999;34:1083–1088. doi: 10.1016/S0272-6386(99)70014-4. - DOI - PubMed